Home Healthcare Pharmaceuticals Intravenous to Subcutaneous Drug Repositioning Market

Intravenous to Subcutaneous Drug Repositioning Market Size, Share & Trends Analysis Report By Product (Devices, Drugs), By Therapeutic Indication (Cardiology, Oncology, Pulmonary Arterial Hypertension, Hematology, Others), By End User (Hospitals & Clinics, Research Facilities, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 24, 2026 | Author: Debashree Bora | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Intravenous to Subcutaneous Drug Repositioning Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Devices
      1. Wearable SC Injectors
      2. Wearable SC Infusers
    2. Drugs
      1. Cancer Drugs
      2. Blood Factors
      3. Immunoglobulin G
      4. Antibiotics
      5. Remodulin
      6. Others
  2. Intravenous to Subcutaneous Drug Repositioning Market, By Therapeutic Indication 2022-2034 (USD MILLION/ Units)
    1. Cardiology
    2. Oncology
    3. Pulmonary Arterial Hypertension
    4. Hematology
    5. Others
  3. Intravenous to Subcutaneous Drug Repositioning Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals & Clinics
    2. Research Facilities
    3. Others
  4. Regional Intravenous to Subcutaneous Drug Repositioning Market
    1. North America
      1. North America Intravenous to Subcutaneous Drug Repositioning Market By Product 2022-2034 (USD MILLION/ Units)
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
      2. North America Intravenous to Subcutaneous Drug Repositioning Market By Therapeutic Indication 2022-2034 (USD MILLION/ Units)
        1. Cardiology
        2. Oncology
        3. Pulmonary Arterial Hypertension
        4. Hematology
        5. Others
      3. North America Intravenous to Subcutaneous Drug Repositioning Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Facilities
        3. Others
      4. U.S.
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      5. Canada
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
    2. Europe
      1. Europe Intravenous to Subcutaneous Drug Repositioning Market By Product 2022-2034 (USD MILLION/ Units)
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
      2. Europe Intravenous to Subcutaneous Drug Repositioning Market By Therapeutic Indication 2022-2034 (USD MILLION/ Units)
        1. Cardiology
        2. Oncology
        3. Pulmonary Arterial Hypertension
        4. Hematology
        5. Others
      3. Europe Intravenous to Subcutaneous Drug Repositioning Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Facilities
        3. Others
      4. U.K.
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      5. Germany
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      6. France
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      7. Spain
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      8. Italy
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      9. Russia
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      10. Nordic
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      11. Benelux
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      12. Rest of Europe
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
    3. APAC
      1. APAC Intravenous to Subcutaneous Drug Repositioning Market By Product 2022-2034 (USD MILLION/ Units)
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
      2. APAC Intravenous to Subcutaneous Drug Repositioning Market By Therapeutic Indication 2022-2034 (USD MILLION/ Units)
        1. Cardiology
        2. Oncology
        3. Pulmonary Arterial Hypertension
        4. Hematology
        5. Others
      3. APAC Intravenous to Subcutaneous Drug Repositioning Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Facilities
        3. Others
      4. China
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      5. Korea
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      6. Japan
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      7. India
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      8. Australia
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      9. Taiwan
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      10. South East Asia
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      11. Rest of Asia-Pacific
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
    4. Middle East and Africa
      1. Middle East and Africa Intravenous to Subcutaneous Drug Repositioning Market By Product 2022-2034 (USD MILLION/ Units)
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
      2. Middle East and Africa Intravenous to Subcutaneous Drug Repositioning Market By Therapeutic Indication 2022-2034 (USD MILLION/ Units)
        1. Cardiology
        2. Oncology
        3. Pulmonary Arterial Hypertension
        4. Hematology
        5. Others
      3. Middle East and Africa Intravenous to Subcutaneous Drug Repositioning Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Facilities
        3. Others
      4. UAE
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      5. Turkey
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      6. Saudi Arabia
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      7. South Africa
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      8. Egypt
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      9. Nigeria
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      10. Rest of MEA
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
    5. LATAM
      1. LATAM Intravenous to Subcutaneous Drug Repositioning Market By Product 2022-2034 (USD MILLION/ Units)
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
      2. LATAM Intravenous to Subcutaneous Drug Repositioning Market By Therapeutic Indication 2022-2034 (USD MILLION/ Units)
        1. Cardiology
        2. Oncology
        3. Pulmonary Arterial Hypertension
        4. Hematology
        5. Others
      3. LATAM Intravenous to Subcutaneous Drug Repositioning Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Facilities
        3. Others
      4. Brazil
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      5. Mexico
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      6. Argentina
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      7. Chile
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      8. Colombia
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
      9. Rest of LATAM
        1. Devices
          1. Wearable SC Injectors
          2. Wearable SC Infusers
        2. Drugs
          1. Cancer Drugs
          2. Blood Factors
          3. Immunoglobulin G
          4. Antibiotics
          5. Remodulin
          6. Others
        3. Cardiology
        4. Oncology
        5. Pulmonary Arterial Hypertension
        6. Hematology
        7. Others
        8. Hospitals & Clinics
        9. Research Facilities
        10. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.